Doses of factor VIII in factor VIII-VWF concentrates that are recommended in VWD patients who are unresponsive to desmopressin
| Type of bleeding . | FVIII:C dose,* U/kg . | No. of infusions . | Objective . |
|---|---|---|---|
| Major surgery | 50 | Once a day or every other day | Maintain FVIII:C 80-100 IU/dL for the first 2 days and then > 50 IU/dL for 5-7 days |
| Minor surgery; cesarean section | 30 | Once a day or every other day | Maintain FVIII:C > 30 IU/dL for at least 5-7 days |
| Dental extractions | 20-40 | Single | Obtain FVIII:C >30-50 IU/dL; subsequent infusions on clinical need |
| Delivery and/or epidural anesthesia | 30-40 | Single | Obtain FVIII:C > 50 IU/dL; subsequent infusions on clinical need |
| Spontaneous or posttraumatic bleeding | 20-40 | Single | Obtain FVIII:C > 30-50 IU/dL; subsequent infusions on clinical need |
| Severe frequent bleeding (gastrointestinal, menorrhagia, hemarthrosis) | 20-40 | Twice to thrice weekly | Short-term control: dose adjusted on the basis of clinical response; life-long prophylaxis: still experimental, to be adopted within clinical trials |
| Type of bleeding . | FVIII:C dose,* U/kg . | No. of infusions . | Objective . |
|---|---|---|---|
| Major surgery | 50 | Once a day or every other day | Maintain FVIII:C 80-100 IU/dL for the first 2 days and then > 50 IU/dL for 5-7 days |
| Minor surgery; cesarean section | 30 | Once a day or every other day | Maintain FVIII:C > 30 IU/dL for at least 5-7 days |
| Dental extractions | 20-40 | Single | Obtain FVIII:C >30-50 IU/dL; subsequent infusions on clinical need |
| Delivery and/or epidural anesthesia | 30-40 | Single | Obtain FVIII:C > 50 IU/dL; subsequent infusions on clinical need |
| Spontaneous or posttraumatic bleeding | 20-40 | Single | Obtain FVIII:C > 30-50 IU/dL; subsequent infusions on clinical need |
| Severe frequent bleeding (gastrointestinal, menorrhagia, hemarthrosis) | 20-40 | Twice to thrice weekly | Short-term control: dose adjusted on the basis of clinical response; life-long prophylaxis: still experimental, to be adopted within clinical trials |
It is preferable that FVIII/VWF concentrates are labeled for both FVIII:C and VWF:RCo content and with VWF/FVIII ≥ 1.